Stay updated on Eli Lilly and Company Press Releases

Sign up to get notified when there's something new on the Eli Lilly and Company Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Eli Lilly and Company Press Releases page

  1. Check
    6 days ago
    Change Detected
    Summary
    Eli Lilly has received FDA approval for an updated label for Amyvid to aid in Alzheimer's diagnosis, and has declared a third-quarter dividend of $1.50 per share. Additionally, promising results were reported for Lilly's insulin efsitora alfa and oral GLP-1 orforglipron in diabetes management.
    Difference
    100%
    Check dated 2025-06-25T23:13:32.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Eli Lilly is set to acquire Verve Therapeutics to enhance treatments for cardiovascular risk, and it will offer all approved doses of Zepbound through its Self Pay Pharmacy Solutions at a price of $499/month or less. Notably, previous announcements regarding a collaboration with Purdue University and executive leadership transitions have been removed.
    Difference
    100%
    Check dated 2025-06-18T21:13:11.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    Eli Lilly has announced its participation in the Goldman Sachs 46th Annual Global Health Care Conference and presented new clinical data for its investigational FRα targeting ADC in ovarian cancer. However, the company has removed information regarding its second-quarter dividend declaration and participation in the Bank of America Securities Healthcare Conference.
    Difference
    100%
    Check dated 2025-06-04T14:19:49.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Eli Lilly has made significant announcements regarding its expansion into pain management through the acquisition of SiteOne Therapeutics, and it has received marketing authorization in Australia for Kisunla (donanemab) for Alzheimer's treatment. Additionally, there are updates on presentations at the 2025 ASCO Annual Meeting and concerns regarding insurance coverage for obesity medications.
    Difference
    100%
    Check dated 2025-05-28T10:13:50.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Eli Lilly has announced significant advancements, including the superior weight loss results of Zepbound over Wegovy, a planned $250 million investment in collaboration with Purdue University, and transitions in executive leadership. Notably, previous statements regarding donanemab's marketing authorization and expansions of the LillyDirect platform have been removed.
    Difference
    100%
    Check dated 2025-05-14T04:52:37.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    Eli Lilly has declared a second-quarter 2025 dividend of $1.50 per share and reported a significant revenue increase of 45% in Q1 2025, driven by product growth. Additionally, the company will participate in the Bank of America Securities 2025 Healthcare Conference.
    Difference
    100%
    Check dated 2025-05-07T00:58:39.000Z thumbnail image

Stay in the know with updates to Eli Lilly and Company Press Releases

Enter your email address, and we'll notify you when there's something new on the Eli Lilly and Company Press Releases page.